Protagonist Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Protagonist Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Protagonist Therapeutics Inc
Rating: 1.498972125
Author: Trendlyne DVM scores

Momentum Trap

about

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology,...

102.40 -3.15 (-2.98%)

135.62% Gain from 52W Low

41,192.4

XNAS Volume

XNAS 15 May, 2026 10:35 AM (EDT)

Insider Trade

Bryan Giraudo, Independent Director at Protagonist Therapeutics, sells 59.1K shares worth $5.9 mn See details

Low Financial Strength

22.2 / 100

Expensive Valuation

5.3 / 100

Technically Bullish

70.1 / 100

Momentum Trap These stocks have weak financials and expensive valuation. Buying interest may quickly dissipate. Investors should exercise caution View Similar Embed DVM

117

1Yr Price target upside is 15%

12 analysts

Protagonist Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Protagonist Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology,...

135.62% Gain from 52W Low

SWOT Analysis

Protagonist Therapeutics Inc Live Price Chart